EUCTR2012-001154-26-Outside-EU/EEA进行中（未招募）不适用
A phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumours
Pediatric Brain Tumour Consortium0 个研究点目标入组 55 人开始时间: 2012年3月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must be less than or equal to 21
- •Histology confirmed primary CNS tumour
- •Recurrent, progressive, or refactory disease
- •No known curative therapy available
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with any clincially significant unrelated systemic illness
- •Patients receiving any other anticancer or investigational drug therapy
- •Patients, ages 1-17, with uncontrolled hypertension
- •Patients with prior treatment with AZD2171
研究者
相似试验
已完成
1 期
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS TumorsChildhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Cerebral Anaplastic AstrocytomaChildhood Cerebral AstrocytomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood Infratentorial EpendymomaChildhood OligodendrogliomaChildhood Spinal Cord NeoplasmChildhood Supratentorial EpendymomaRecurrent Childhood Brain NeoplasmRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway GliomaNCT00326664National Cancer Institute (NCI)55
进行中（未招募）
不适用
AZD2171 to treat children and adolescents with solid tumours or acute myelogenous leukemiaEUCTR2012-001155-39-Outside-EU/EEAAstraZeneca AB40
已完成
不适用
Phase II Study of AZD9291 in patients with advanced stage non-small cell lung cancer following prior EGFR TKI Therapy with EGFR and T790M mutations detected in plasma circulating tumor DNA (PLASMA)NeoplasmsKCT0003197ational University Cancer Institute108
招募中
不适用
Study of AZD1775 in combination with paclitaxel, in advanced gastric adenocarcinoma patients harboring TP53 mutation as a second-line chemotherapyNeoplasmsKCT0004071Samsung Medical Center25
进行中（未招募）
1 期
A Phase 1 and 2 Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of AZD8233 Following a Multiple Subcutaneous Dose Administration in Japanese Participants With DyslipidemiaDyslipidemiaJPRN-jRCT2051210041Hibi Kazushige91